JP Patent

JP2022502492A — 骨髄増殖性疾患の治療法

Assigned to Impact Biomedicines Inc · Expires 2022-01-11 · 4y expired

What this patent protects

本開示は、チアミン欠乏の軽減法を提供する。【選択図】なし

USPTO Abstract

本開示は、チアミン欠乏の軽減法を提供する。【選択図】なし

Drugs covered by this patent

Inrebic (FEDRATINIB HYDROCHLORIDE) · Bristol-Myers Squibb

Patent Metadata

Patent number: JP2022502492A
Jurisdiction: JP
Classification: —
Expires: 2022-01-11
Drug substance claim: No
Drug product claim: No
Assignee: Impact Biomedicines Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.